Long-term Results after Hyaluronan-based MACT for the Treatment of Cartilage Lesions of the Patellofemoral Joint

Elizaveta Kon, Giuseppe Filardo, Alberto Gobbi, Massimo Berruto, Luca Andriolo, Paolo Ferrua, Ilaria Crespiatico, Maurilio Marcacci

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Cartilage lesions of the patellofemoral joint are a challenging condition. Hyaluronan-based matrix-assisted autologous chondrocyte transplantation (MACT) has been shown to offer a significant improvement in the short term but has a tendency to worsen at midterm follow-up. Hypothesis: Patients treated with MACT for lesions of the articular surface of the patellofemoral joint will present further clinical worsening at long-term follow-up. Study Design: Case series; Level of evidence, 4. Methods: Thirty-two patients with full-thickness chondral lesions in the patellofemoral joint were treated with hyaluronan-based MACT and were prospectively evaluated preoperatively and at 2-, 5-, and 10-year follow-up. The mean defect size was 4.45 cm2. There were 20 lesions located on the patella and 8 on the trochlea, and 4 patients had multiple lesions: 3 with patellar and trochlear lesions and 1 with patellar and lateral femoral condyle lesions. Results were evaluated using International Knee Documentation Committee (IKDC) subjective scores, EuroQol visual analog scale (EQ VAS) scores, and Tegner scores. Surgical and clinical failures were documented. Results: All scores showed a statistically significant improvement at 2-, 5-, and 10-year follow-up with respect to the preoperative level. No worsening was observed at the last follow-up, and results were stable up to 10 years. The improvement in mean (±SD) outcome scores from preoperatively to 2-, 5-, and 10-year follow-up was as follows: IKDC, from 46.0 ± 19.8 to 77.1 ± 17.4, 72.0 ± 20.4, and 78.6 ± 16.4, respectively; Tegner, from 2.5 ± 1.4 to 4.7 ± 1.8, 4.7 ± 1.6, and 4.4 ± 1.5, respectively; and EQ VAS, from 56.9 ± 18.4 to 81.7 ± 13.2, 79.2 ± 17.9, and 78.9 ± 1.7, respectively. Four patients did not achieve significant clinical improvement, and 1 of these patients required further surgical treatment. All failures were female patients with patellar defects, and 3 of them had degenerative lesions and underwent a previous or combined realignment procedure. Conclusion: The clinical results of hyaluronan-based MACT treatment of chondral lesions of the patellofemoral joint do not worsen over time but remain stable and show a low rate of failure at long-term follow-up.

Original languageEnglish
Pages (from-to)602-608
Number of pages7
JournalAmerican Journal of Sports Medicine
Volume44
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Patellofemoral Joint
Autologous Transplantation
Hyaluronic Acid
Chondrocytes
Cartilage
Visual Analog Scale
Documentation
Knee
Therapeutics
Patella
Thigh
Joints
Bone and Bones

Keywords

  • chondral lesions
  • chondrocytes
  • long-term follow-up
  • MACT
  • patellofemoral joint
  • scaffold

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Long-term Results after Hyaluronan-based MACT for the Treatment of Cartilage Lesions of the Patellofemoral Joint. / Kon, Elizaveta; Filardo, Giuseppe; Gobbi, Alberto; Berruto, Massimo; Andriolo, Luca; Ferrua, Paolo; Crespiatico, Ilaria; Marcacci, Maurilio.

In: American Journal of Sports Medicine, Vol. 44, No. 3, 01.03.2016, p. 602-608.

Research output: Contribution to journalArticle

Kon, E, Filardo, G, Gobbi, A, Berruto, M, Andriolo, L, Ferrua, P, Crespiatico, I & Marcacci, M 2016, 'Long-term Results after Hyaluronan-based MACT for the Treatment of Cartilage Lesions of the Patellofemoral Joint', American Journal of Sports Medicine, vol. 44, no. 3, pp. 602-608. https://doi.org/10.1177/0363546515620194
Kon, Elizaveta ; Filardo, Giuseppe ; Gobbi, Alberto ; Berruto, Massimo ; Andriolo, Luca ; Ferrua, Paolo ; Crespiatico, Ilaria ; Marcacci, Maurilio. / Long-term Results after Hyaluronan-based MACT for the Treatment of Cartilage Lesions of the Patellofemoral Joint. In: American Journal of Sports Medicine. 2016 ; Vol. 44, No. 3. pp. 602-608.
@article{265fe003b0834952bf43bfafb263ebf9,
title = "Long-term Results after Hyaluronan-based MACT for the Treatment of Cartilage Lesions of the Patellofemoral Joint",
abstract = "Background: Cartilage lesions of the patellofemoral joint are a challenging condition. Hyaluronan-based matrix-assisted autologous chondrocyte transplantation (MACT) has been shown to offer a significant improvement in the short term but has a tendency to worsen at midterm follow-up. Hypothesis: Patients treated with MACT for lesions of the articular surface of the patellofemoral joint will present further clinical worsening at long-term follow-up. Study Design: Case series; Level of evidence, 4. Methods: Thirty-two patients with full-thickness chondral lesions in the patellofemoral joint were treated with hyaluronan-based MACT and were prospectively evaluated preoperatively and at 2-, 5-, and 10-year follow-up. The mean defect size was 4.45 cm2. There were 20 lesions located on the patella and 8 on the trochlea, and 4 patients had multiple lesions: 3 with patellar and trochlear lesions and 1 with patellar and lateral femoral condyle lesions. Results were evaluated using International Knee Documentation Committee (IKDC) subjective scores, EuroQol visual analog scale (EQ VAS) scores, and Tegner scores. Surgical and clinical failures were documented. Results: All scores showed a statistically significant improvement at 2-, 5-, and 10-year follow-up with respect to the preoperative level. No worsening was observed at the last follow-up, and results were stable up to 10 years. The improvement in mean (±SD) outcome scores from preoperatively to 2-, 5-, and 10-year follow-up was as follows: IKDC, from 46.0 ± 19.8 to 77.1 ± 17.4, 72.0 ± 20.4, and 78.6 ± 16.4, respectively; Tegner, from 2.5 ± 1.4 to 4.7 ± 1.8, 4.7 ± 1.6, and 4.4 ± 1.5, respectively; and EQ VAS, from 56.9 ± 18.4 to 81.7 ± 13.2, 79.2 ± 17.9, and 78.9 ± 1.7, respectively. Four patients did not achieve significant clinical improvement, and 1 of these patients required further surgical treatment. All failures were female patients with patellar defects, and 3 of them had degenerative lesions and underwent a previous or combined realignment procedure. Conclusion: The clinical results of hyaluronan-based MACT treatment of chondral lesions of the patellofemoral joint do not worsen over time but remain stable and show a low rate of failure at long-term follow-up.",
keywords = "chondral lesions, chondrocytes, long-term follow-up, MACT, patellofemoral joint, scaffold",
author = "Elizaveta Kon and Giuseppe Filardo and Alberto Gobbi and Massimo Berruto and Luca Andriolo and Paolo Ferrua and Ilaria Crespiatico and Maurilio Marcacci",
year = "2016",
month = "3",
day = "1",
doi = "10.1177/0363546515620194",
language = "English",
volume = "44",
pages = "602--608",
journal = "American Journal of Sports Medicine",
issn = "0363-5465",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Long-term Results after Hyaluronan-based MACT for the Treatment of Cartilage Lesions of the Patellofemoral Joint

AU - Kon, Elizaveta

AU - Filardo, Giuseppe

AU - Gobbi, Alberto

AU - Berruto, Massimo

AU - Andriolo, Luca

AU - Ferrua, Paolo

AU - Crespiatico, Ilaria

AU - Marcacci, Maurilio

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background: Cartilage lesions of the patellofemoral joint are a challenging condition. Hyaluronan-based matrix-assisted autologous chondrocyte transplantation (MACT) has been shown to offer a significant improvement in the short term but has a tendency to worsen at midterm follow-up. Hypothesis: Patients treated with MACT for lesions of the articular surface of the patellofemoral joint will present further clinical worsening at long-term follow-up. Study Design: Case series; Level of evidence, 4. Methods: Thirty-two patients with full-thickness chondral lesions in the patellofemoral joint were treated with hyaluronan-based MACT and were prospectively evaluated preoperatively and at 2-, 5-, and 10-year follow-up. The mean defect size was 4.45 cm2. There were 20 lesions located on the patella and 8 on the trochlea, and 4 patients had multiple lesions: 3 with patellar and trochlear lesions and 1 with patellar and lateral femoral condyle lesions. Results were evaluated using International Knee Documentation Committee (IKDC) subjective scores, EuroQol visual analog scale (EQ VAS) scores, and Tegner scores. Surgical and clinical failures were documented. Results: All scores showed a statistically significant improvement at 2-, 5-, and 10-year follow-up with respect to the preoperative level. No worsening was observed at the last follow-up, and results were stable up to 10 years. The improvement in mean (±SD) outcome scores from preoperatively to 2-, 5-, and 10-year follow-up was as follows: IKDC, from 46.0 ± 19.8 to 77.1 ± 17.4, 72.0 ± 20.4, and 78.6 ± 16.4, respectively; Tegner, from 2.5 ± 1.4 to 4.7 ± 1.8, 4.7 ± 1.6, and 4.4 ± 1.5, respectively; and EQ VAS, from 56.9 ± 18.4 to 81.7 ± 13.2, 79.2 ± 17.9, and 78.9 ± 1.7, respectively. Four patients did not achieve significant clinical improvement, and 1 of these patients required further surgical treatment. All failures were female patients with patellar defects, and 3 of them had degenerative lesions and underwent a previous or combined realignment procedure. Conclusion: The clinical results of hyaluronan-based MACT treatment of chondral lesions of the patellofemoral joint do not worsen over time but remain stable and show a low rate of failure at long-term follow-up.

AB - Background: Cartilage lesions of the patellofemoral joint are a challenging condition. Hyaluronan-based matrix-assisted autologous chondrocyte transplantation (MACT) has been shown to offer a significant improvement in the short term but has a tendency to worsen at midterm follow-up. Hypothesis: Patients treated with MACT for lesions of the articular surface of the patellofemoral joint will present further clinical worsening at long-term follow-up. Study Design: Case series; Level of evidence, 4. Methods: Thirty-two patients with full-thickness chondral lesions in the patellofemoral joint were treated with hyaluronan-based MACT and were prospectively evaluated preoperatively and at 2-, 5-, and 10-year follow-up. The mean defect size was 4.45 cm2. There were 20 lesions located on the patella and 8 on the trochlea, and 4 patients had multiple lesions: 3 with patellar and trochlear lesions and 1 with patellar and lateral femoral condyle lesions. Results were evaluated using International Knee Documentation Committee (IKDC) subjective scores, EuroQol visual analog scale (EQ VAS) scores, and Tegner scores. Surgical and clinical failures were documented. Results: All scores showed a statistically significant improvement at 2-, 5-, and 10-year follow-up with respect to the preoperative level. No worsening was observed at the last follow-up, and results were stable up to 10 years. The improvement in mean (±SD) outcome scores from preoperatively to 2-, 5-, and 10-year follow-up was as follows: IKDC, from 46.0 ± 19.8 to 77.1 ± 17.4, 72.0 ± 20.4, and 78.6 ± 16.4, respectively; Tegner, from 2.5 ± 1.4 to 4.7 ± 1.8, 4.7 ± 1.6, and 4.4 ± 1.5, respectively; and EQ VAS, from 56.9 ± 18.4 to 81.7 ± 13.2, 79.2 ± 17.9, and 78.9 ± 1.7, respectively. Four patients did not achieve significant clinical improvement, and 1 of these patients required further surgical treatment. All failures were female patients with patellar defects, and 3 of them had degenerative lesions and underwent a previous or combined realignment procedure. Conclusion: The clinical results of hyaluronan-based MACT treatment of chondral lesions of the patellofemoral joint do not worsen over time but remain stable and show a low rate of failure at long-term follow-up.

KW - chondral lesions

KW - chondrocytes

KW - long-term follow-up

KW - MACT

KW - patellofemoral joint

KW - scaffold

UR - http://www.scopus.com/inward/record.url?scp=84960155271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960155271&partnerID=8YFLogxK

U2 - 10.1177/0363546515620194

DO - 10.1177/0363546515620194

M3 - Article

AN - SCOPUS:84960155271

VL - 44

SP - 602

EP - 608

JO - American Journal of Sports Medicine

JF - American Journal of Sports Medicine

SN - 0363-5465

IS - 3

ER -